Get started
Author

Dan Norris

Observed names: Dan A. Norris, Norris, Dan
OpenAlex ID: A5069140455
Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides
2016 · Elizabeth J. Ackermann, Shuling Guo, et al. · Amyloid · 143
Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals
2013 · Gene Hung, Xiaokun Xiao, et al. · Nucleic Acid Therapeutics · 125
Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series
2025 · Neil A Shneider, Matthew B Harms, et al. · The Lancet · 51
Translating Antisense Technology into a Treatment for Huntington’s Disease
2018 · Roger M. Lane, Anne Smith, et al. · Methods in molecular biology · 39
Immunogenicity Assessment of Inotersen, a 2′- O -(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety
2020 · Rosie Z. Yu, Yanfeng Wang, et al. · Nucleic Acid Therapeutics · 27
Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
2013 · Thomas A. Bell, Mark J. Graham, et al. · Journal of Lipid Research · 21
A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.
2013 · David S. Hong, Anas Younes, et al. · Journal of Clinical Oncology · 17
Translational Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Strategy to Support RG6042 Dose Selection in Huntington’s Disease (HD) (S16.005)
2019 · Patricia Sanwald Ducray, Nicolas Frances, et al. · Neurology · 6
In the wake of heroes
2014 · Norris, Dan · Maryland Shared Open Access Repository (USMAI Consortium)
PDF
Works count: 10
Citation count: 428
H-index: 7
I10-index: 7
Year
Topic
Type